VERA Stock Analysis: Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical developme
- Latest close
- $34
- 20-day change
- +8.77%
- Trend state
- NEUTRAL
- Classification
- Healthcare · Biotechnology
Market context
Vera Therapeutics, Inc. moved +8.77% over the latest 20-session window. BullRecon currently classifies the broader setup as NEUTRAL.
Latest report
The latest cached company filing period (FY2025 · -$299.6M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 5.0/6, while Value is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.